Who Really Makes Boots No7 Skincare? The Answer May Surprise You

Summary

Business model and operational evolution

• Boots’ vertical-integration origins: Boots began as a Nottingham chemist in 1849 and launched No. 7 in 1935 with 11 skincare products. For decades, Boots both sold and manufactured No. 7 through Boots Contract Manufacturing (BCM). BCM also made products for other brands, operating as both a contract manufacturer and an internal production arm.
• Shift to outsourced manufacturing: After Boots became part of Walgreens Boots Alliance in 2014, the group agreed in 2017 to sell BCM, including its Nottingham factory, to French contract manufacturer Fareva. Fareva became a main manufacturing partner for Boots’ own-brand beauty products, marking a shift from owning production assets to relying on a specialist supplier.
• Factory consolidation: In 2023, Fareva announced plans to wind down manufacturing in Nottingham, citing reduced business and spare capacity. Production was expected to move to its Pontyclun, Wales, site by early 2024. Around 150 roles were planned there, while hundreds of Nottingham jobs were at risk. Research and development, product testing, commercial teams, and procurement were expected to remain in Nottingham.
• Supply-chain transparency limitation: Fareva has been identified as a No. 7 manufacturer, but neither company provides a product-by-product factory list. The video therefore cannot identify which facility made any particular bottle.
• Brand ownership and expansion: No. 7 became a separate business, the No. 7 Beauty Company, in 2021, with the ambition of growing it as a global brand. It had already been sold in Walgreens stores in the US from 2012. The video says No. 7 is now sold in thousands of stores across around 30 markets. Following Sycamore Partners’ 2025 takeover of Walgreens Boots Alliance, Boots became the standalone Boots Group, with No. 7 in its brand family.

Product, research and development, and marketing

• Research as differentiation: No. 7’s Protect & Perfect serum gained attention after BBC Horizon reported research suggesting an effect on fibrillin-1, a protein involved in skin structure. Boots later funded a double-blind, placebo-controlled trial with the University of Manchester.
• Future Renew launch playbook: The 2022 Future Renew line was built around “pepticology,” a peptide blend developed with the University of Manchester over about 15 years. The range expanded from a serum to include night and eye serums, day cream with SPF 40, night cream, and an SPF 50 product.
• Positioning: No. 7 is positioned above low-cost supermarket own-label skincare such as Lacura and Cien, but below many luxury brands. Its differentiation combines research, a recognizable brand, Boots’ retail distribution and service, and a broader product range.
• Marketing risk: The Advertising Standards Authority (ASA) banned a 2024 Future Renew advert whose “don’t regret, just reverse” message was judged liable to downplay the importance of sun protection. The video also cites a 2005 ASA ruling against a No. 7 anti-cellulite advert. The lesson for marketing teams is that even products with credible research can create regulatory and reputational risks if campaign claims overstate benefits or conflict with health guidance.

Metrics and evidence cited

• Historical product development: No. 7 launched in 1935 with 11 skincare products; colour cosmetics followed in 1937. Body care, foundation, and men’s skincare were added much later, in 2007.
• Manufacturing partnership: Fareva’s 2017 agreement was described as a 10-year deal. At the time, Fareva reportedly employed nearly 10,000 people and operated factories in 11 countries.
• Research record: Over roughly 20 years, Boots and the University of Manchester reportedly filed 16 patent applications together and published 61 academic papers.
• Protect & Perfect trial: Sixty volunteers aged 45–80 were split between serum and placebo groups. The University reported that 70% of serum users had significantly fewer wrinkles after 12 months compared with the placebo group. Important caveats include that Boots funded the study, the sample was small, and the placebo group was followed for six months. The 12-month comparison relied on a statistical projection.
• Future Renew demand and sales: Boots reported a waiting list of 94,000 before launch and one product sold every two seconds on launch day in 2022. The serum became Boots’ best-selling skincare product in 2023. Refinery29 reportedly said five months’ worth of stock sold out in one day at the UK launch.
• Pricing: At launch, a 25 ml Future Renew serum cost £34.95. The video puts a 50 ml bottle at around £48 before offers—about £96 per 100 ml. It notes that the product is frequently promoted through offers such as “three for two,” suggesting full-price purchases may not be necessary.

Frameworks and actionable playbooks

Three-question check for “clinically proven” claims

1. Who paid, and how many people were studied? Disclose funding and assess whether the sample is large enough to support the claim.
2. Compared with what? Look for a placebo or active comparator; a cream’s moisturizing base may itself make skin look smoother.
3. What exactly improved? Distinguish measurable changes from claims about the “appearance” of lines, which may reflect temporary hydration rather than lasting wrinkle reduction.

Other guidance

• Ingredient-label check: Ingredients are listed in descending order by weight, generally down to the 1% threshold. Check whether a promoted “hero” ingredient appears high on the list or near the bottom.
• Expectation-setting for product claims: The video’s assessment is that No. 7 has more published evidence than many beauty brands, but the demonstrated effect is modest and does not establish a dramatic or life-changing result.
• Customer and product segmentation: The video suggests that basic moisturiser and daily sunscreen may be sufficient for people without specific concerns. No. 7 may suit shoppers seeking a more targeted, evidence-backed product at a mid-market price. An additional serum may be unnecessary for someone already using a prescription retinoid. For conditions such as acne, rosacea, or eczema, the video recommends seeking advice from a pharmacist or GP.
• Sun protection: Sunscreen remains central to preventing sun damage and should not be treated as replaceable by an anti-ageing serum.

Presenter and sources

• Presenter: Unnamed narrator, British Truth Report.
• Sources and organizations cited: Boots; Fareva; Walgreens Boots Alliance; Sycamore Partners; University of Manchester; Professor Chris Griffiths; BBC Horizon; McGill University and a cited McGill science writer; Margaret McCartney; Which?; PA news agency; Refinery29; and the Advertising Standards Authority (ASA).